Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEXIM

Financiado

Cerrado

A Next generation targeted immuno oncology therapy

In spite of enormous medical progress, aggressive forms of cancer remain one of the leading causes of death across the globe. Metastasized prostate, lung, breast and colon cancer account for a combined mortality of approximately 0... ver más

31/10/2019

TargImmune

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

TARGIMMUNE THERAPEUTICS AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-10-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TargImmune

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

subLETHAL From understanding to rational design of next-generation can... 2M€ Cerrado

TIGER Targeted Immunocytokines by CaGing and local Release Cerrado

PLEC2022-009319 Descubrimiento y desarrollo temprano de nuevos activadores d... 380K€ Cerrado

Tumor-Treg-Targeting Training Network for the education of the next generation sc... 1M€ Cerrado

CHEMO-IMMUNE THERAPY A translational approach evaluating novel strategies using c... 100K€ Cerrado

EN_ACTI2NG European Network on Anti Cancer Immuno Therapy Improvement b... 3M€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2019-04-15
Fecha Fin: 2019-10-31

Líder del proyecto

TARGIMMUNE THERAPEUTICS AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In spite of enormous medical progress, aggressive forms of cancer remain one of the leading causes of death across the globe. Metastasized prostate, lung, breast and colon cancer account for a combined mortality of approximately 0,8 M lives in Europe per year. Immunotherapies, activating patient’s own immune system to target and destroy tumor cells, have shown enormous promise in the treatment of metastatic forms of cancer, creating a huge market with a €100B potential in 2022. However, these drugs are only effective in 15-25% of patients, and their use is associated with severe side effects. Therefore, there is an unmet medical need for next-generation of cancer immunotherapies with improved safety and consistent efficacy in a broader patient population. TargImmune, is a Switzerland based company with a mission to develop novel targeted immuno-oncology drugs that will improve the treatment of patients with aggressive tumors. Using our proprietary treatment technology based on the targeted intracellular delivery of an RNA-analogue inside the tumor, we will provide novel systemic immune therapy for metastasized cancer with less side effects and improved effectiveness across all patient populations. Currently we have 3 drugs in development for prostate, breast cancer and solid tumors. All potential pipeline candidates address a highly attractive immune-oncology market, with the total addressable market for our first asset of €1.7B. The product is predicted to generate €466M of cumulative annual revenues through 10 % royalties over sales in the first 5 years, as a part of licensing deal with a large pharmaceutical company. After initial investment round, we currently seek for additional funding to further develop our pipeline candidates. In the NEXIM project, we will finalize an investor-ready business plan, required to ensure additional investments. The project will also include an analysis of the competitor and investor landscape and market positioning.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores